CF
KNSA icon

Corebridge Financial’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Corebridge Financial’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,979
Closed -$355K – 1451
2025
Q1 		$355K Buy
15,979
+549
+4% +$11.3K ﹤0.01% 1767
2024
Q4 		$305K Sell
15,430
-819
-5% -$18.7K ﹤0.01% 1935
2024
Q3 		$406K Sell
16,249
-123
-0.8% -$3K ﹤0.01% 1838
2024
Q2 		$306K Buy
+16,372
New +$307K ﹤0.01% 1957

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Corebridge Financial's KNSA Position: Q2 2025 in Review

Corebridge Financial sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2025, closing a stake of 15,979 shares — an estimated $355K sold.

Corebridge Financial first reported a position in KNSA in Q2 2024 and held it in 4 quarters. The position peaked at $406K in Q3 2024. 189 funds tracked by Wall St. Rank hold KNSA as of Q2 2025.

  • Corebridge Financial reported no remaining Kiniksa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 15,979 Kiniksa Pharmaceuticals shares in Q2 2025, an estimated $355K.
  • Corebridge Financial first reported a position in Kiniksa Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Kiniksa Pharmaceuticals position peaked at $406K in Q3 2024.
  • 189 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.